Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
Beyond the Shelf: Funko’s Vision for Future Collectibles
Tomorrow’s World Today® Podcast
17 minutes
1 month ago
Beyond the Shelf: Funko’s Vision for Future Collectibles
What powers a global fandom machine? We sat down with Funko’s Chief Product Officer, Husnal Shah, to trace the line from a week‑one Disney sellout to 900 licenses and a milestone few toy companies reach in decades. We break down the three Cs—Culture, Creativity, Commerce—that decide which figures get made, why certain iconic moments jump off the shelf, and how a recognizable form can still surprise you when it captures the perfect story beat. 🪀 Husnal opens the door to Funko’s incubation lab,...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
